Carrie Wade
Former Director, Harm Reduction Policy; Former Resident Senior Fellow
About Carrie
Carrie L. Wade was responsible for directing R Street’s harm reduction agenda. Her research was primarily interested in how public health initiatives can prevent the incidence of addiction and reduce the negative societal and personal consequences that result from substance use.
areas of expertise
Media Request
For general and media inquiries and to book our experts, please contact: [email protected]
More from Carrie
R Sheets Harm Reduction, Tobacco Harm Reduction
E-Cigarettes: Frequently Asked Questions
Carrie Wade
Jan 22, 2020
Policy Studies Competition Policy, Disintermediation
Bringing Hormonal Birth Control Over The Counter
Chelsea Boyd, Courtney Joslin, Carrie Wade
Nov 27, 2019
Policy Studies Federal Government Affairs, Harm Reduction, Tobacco Harm Reduction
Tobacco Harm Reduction: Evidence Update
Carrie Wade, Chelsea Boyd
Aug 7, 2019
R Sheets Harm Reduction, Opioid Harm Reduction
R Sheet on Opioid and Injection Drug Use Harm Reduction
Carrie Wade, Chelsea Boyd
May 29, 2019
R Sheets Harm Reduction, Tobacco Harm Reduction
R Sheet on Tobacco Harm Reduction
Carrie Wade, Chelsea Boyd
May 8, 2019
Policy Studies Harm Reduction, Tobacco Harm Reduction
Think before you ban: The awkward case of e-cigarette flavors
Carrie Wade
June 11, 2018
Policy Studies Harm Reduction, Opioid Harm Reduction
Harm reduction strategies for chronic pain management in the opioid epidemic
Carrie Wade
May 16, 2018
Policy Studies Tobacco Harm Reduction
Bay Area flavored tobacco bans undermine harm reduction
Carrie Wade
Nov 16, 2017
Commentary from Carrie
R Street Responds Harm Reduction, Tobacco Harm Reduction
Examining the trajectory from dual use to harm reduction
Carrie Wade
March 18, 2020
Outreach from Carrie
Coalition Letters Federal Government Affairs, Harm Reduction, Sexual Health
Nation’s Leading Drug Policy Experts Demand Medication Assisted Treatment and COVID-19: Treatment Reforms
Chelsea Boyd, Carrie Wade
April 10, 2020
Congressional Letters Federal Government Affairs, Harm Reduction, Tobacco Harm Reduction
R Street letter to House of Representatives on HR 2339
Chelsea Boyd, Carrie Wade
Feb 24, 2020
Testimony Harm Reduction, Tobacco Harm Reduction
In Opposition to Bill 23-0453, “Flavored Electronic Smoking Device Prohibition Amendment Act of 2019.”
Carrie Wade, Chelsea Boyd
Feb 24, 2020
Regulatory Comments Harm Reduction, Tobacco Harm Reduction
Modified Risk Tobacco Product Applications for VLNTM King and VLNTM Menthol King, Combusted, Filtered Cigarettes Submitted by 22nd Century Group Inc. Docket No. FDA-2019-N-0994
Carrie Wade, Chelsea Boyd
Feb 12, 2020
Congressional Letters Harm Reduction, Tobacco Harm Reduction
Letter to House Energy & Commerce Oversight & Investigations Subcommittee regarding e-cigarette manufacturers’ impact on public health
Carrie Wade, Chelsea Boyd
Feb 5, 2020
Regulatory Comments Harm Reduction, Tobacco Harm Reduction
Docket No. FDA-2017-D-3001-0002 for Modified Risk Tobacco Product Applications for IQOS system with Marlboro Heatsticks, IQOS system with Marlboro Smooth Menthol Heatsticks, and IQOS system with Marlboro Fresh Menthol Heatsticks submitted by Philip Morris Products S.A.
Carrie Wade, Chelsea Boyd
Jan 29, 2020
Testimony Harm Reduction, Tobacco Harm Reduction
R Street Testimony on the National Youth Tobacco Epidemic
Carrie Wade, Chelsea Boyd
Oct 16, 2019
Coalition Letters Harm Reduction, Tobacco Harm Reduction
Coalition Urges President Trump to Protect Adult Vapers by Keeping Flavored Products Legally Available
Carrie Wade
Oct 3, 2019
Coalition Letters Federal Government Affairs, Harm Reduction, Tobacco Harm Reduction
R Street Letter to the House Oversight and Investigations Subcommittee on the Public Health Consequences of the Vaping Ban
Carrie Wade, Chelsea Boyd
Sept 23, 2019
bool(true)
bool(true)
string(2) "50"
Support Our Work
Your donation helps us engage in policy research and outreach in support of free markets and limited, effective government across the country.